Hirokazu Shoji

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 157 publications

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.

Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.

Journal: International journal of clinical oncology

Published: May 28, 2026

ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy-phase II investigator-initiated trial (NCCH2412/MK015).

ENVELOPE: enfortumab vedotin in patients with advanced small bowel adenocarcinoma refractory or intolerant to platinum-based therapy-phase II investigator-initiated trial (NCCH2412/MK015).

Journal: ESMO gastrointestinal oncology

Published: April 20, 2026

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic Cancer.

Journal: The New England journal of medicine

Published: March 25, 2026

Impact of travel costs on disparities in precision oncology clinical trials.

Impact of travel costs on disparities in precision oncology clinical trials.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma.

An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma.

Journal: ESMO gastrointestinal oncology

Published: February 06, 2026

Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan.

Comprehensive Genomic Profiling of Advanced Anal Adenocarcinoma in Japan.

Journal: JCO precision oncology

Published: January 15, 2026

Association of the PD-L1 CPS With the Efficacy of First-Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer.

Association of the PD-L1 CPS With the Efficacy of First-Line Nivolumab Plus Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer.

Journal: Cancer medicine

Published: December 24, 2025

Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.

Zolbetuximab plus chemotherapy in Japanese patients with claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma: a combined subgroup analysis of the phase 3 SPOTLIGHT and GLOW trials.

Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

Published: December 18, 2025

ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.

Journal: Cancer research communications

Published: December 17, 2025

Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer.

Feasibility of antibiotic-assisted fecal microbiota transplantation with immunotherapy for esophageal and gastric cancer.

Journal: Future oncology (London, England)

Published: December 17, 2025

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer.

Journal: Targeted oncology

Published: November 17, 2025

Retrospective Comparison of Capecitabine plus Oxaliplatin and Docetaxel plus S-1 as Adjuvant Chemotherapy for Pathological Stage III Gastric Cancer.

Retrospective Comparison of Capecitabine plus Oxaliplatin and Docetaxel plus S-1 as Adjuvant Chemotherapy for Pathological Stage III Gastric Cancer.

Journal: Oncology

Published: November 07, 2025

Showing 1-12 of 157

Last Updated: 09/26/2026